• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

壁层腹膜切除术的范围不会改变腹腔内化疗的药代动力学。

Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.

作者信息

de Lima Vazquez Vinicius, Stuart O Anthony, Mohamed Faheez, Sugarbaker Paul H

机构信息

Washington Cancer Institute, Washington DC, USA.

出版信息

Cancer Chemother Pharmacol. 2003 Aug;52(2):108-12. doi: 10.1007/s00280-003-0626-8. Epub 2003 May 21.

DOI:10.1007/s00280-003-0626-8
PMID:12759776
Abstract

PURPOSE

To measure the clearance intraperitoneal mitomycin C and doxorubicin in patients having peritonectomy and analyze the impact of the extent of peritoneal resection on pharmacokinetics.

METHODS

A group of 15 patients with peritoneal carcinomatosis were submitted to cytoreductive surgery and heated intraperitoneal chemotherapy. Ten patients received mitomycin C and five, doxorubicin. Six patients underwent total parietal peritonectomy and nine had less-extensive peritonectomy. Pharmacokinetics were determined by sampling peritoneal fluid and blood. Drug concentrations over time, area under the curve ratios and the amount of drug recovered from the peritoneal cavity were calculated and compared between the groups.

RESULTS

The concentrations of mitomycin C over time in the peritoneal fluid and plasma were similar in five patients with total parietal peritonectomy as compared to five patients with less-extensive peritonectomy ( P=0.5350 and 0.6991; Mann-Whitney test). Mitomycin C area under the curve ratio in total peritonectomy patients was 20.5 and 25.7 in patients with less-extensive peritonectomy. The difference in total amount of drug recovered from the peritoneal cavity was not significant (30.6+/-6.188% versus 22.6+/-3.84%, P=0.095). In the studies with doxorubicin, one patient underwent total parietal peritonectomy with similar pharmacokinetics to four patients submitted to partial peritonectomy.

CONCLUSIONS

The extent of parietal peritoneal resection did not affect the pharmacokinetics of intraoperative intraperitoneal chemotherapy. The pharmacological barrier between the abdominopelvic cavity and plasma is not directly related to an intact peritoneum.

摘要

目的

测量接受腹膜切除术患者腹腔内丝裂霉素C和阿霉素的清除率,并分析腹膜切除范围对药代动力学的影响。

方法

一组15例腹膜癌患者接受了肿瘤细胞减灭术和热腹腔内化疗。10例患者接受丝裂霉素C治疗,5例接受阿霉素治疗。6例患者接受了全腹膜切除术,9例接受了范围较小的腹膜切除术。通过采集腹腔液和血液样本测定药代动力学。计算并比较两组随时间变化的药物浓度、曲线下面积比以及从腹腔回收的药物量。

结果

5例接受全腹膜切除术的患者与5例接受范围较小腹膜切除术的患者相比,腹腔液和血浆中丝裂霉素C随时间的浓度相似(P=0.5350和0.6991;Mann-Whitney检验)。全腹膜切除术患者的丝裂霉素C曲线下面积比为20.5,范围较小腹膜切除术患者为25.7。从腹腔回收的药物总量差异不显著(30.6±6.188%对22.6±3.84%,P=0.095)。在阿霉素的研究中,1例接受全腹膜切除术的患者药代动力学与4例接受部分腹膜切除术的患者相似。

结论

腹膜切除范围不影响术中腹腔内化疗的药代动力学。腹腔与血浆之间的药理屏障与完整的腹膜无直接关系。

相似文献

1
Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.壁层腹膜切除术的范围不会改变腹腔内化疗的药代动力学。
Cancer Chemother Pharmacol. 2003 Aug;52(2):108-12. doi: 10.1007/s00280-003-0626-8. Epub 2003 May 21.
2
Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.腹腔内热灌注丝裂霉素C治疗患者中化疗溶液体积引起的药代动力学变化
Cancer Chemother Pharmacol. 2006 May;57(5):703-8. doi: 10.1007/s00280-005-0074-8. Epub 2005 Aug 11.
3
Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies.术中腹腔内热灌注丝裂霉素C及术后早期腹腔内注射5-氟尿嘧啶:药代动力学研究
Oncology. 1998 Mar-Apr;55(2):130-8. doi: 10.1159/000011847.
4
[Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].[细胞减灭术联合腹腔热灌注化疗(IHPC)治疗腹膜癌病:术后发病率、死亡率及短期随访]
Ann Ital Chir. 2008 Jul-Aug;79(4):231-9.
5
Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer.全腹结肠切除术、盆腔腹膜切除术及末端回肠造口术用于非妇科癌症所致黏液性腹膜癌病的手术姑息治疗。
J Surg Oncol. 2003 Aug;83(4):197-203. doi: 10.1002/jso.10270.
6
Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis.腹膜切除术及热灌注化疗在腹膜癌病治疗中的应用
Eur J Surg Oncol. 2000 Aug;26(5):486-91. doi: 10.1053/ejso.1999.0927.
7
Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis.瑞典腹膜切除术和腹腔内热灌注化疗的经验。腹腔内热灌注化疗用于治疗腹膜癌病。
Ann Surg Oncol. 2008 Mar;15(3):745-53. doi: 10.1245/s10434-007-9700-5. Epub 2007 Dec 5.
8
Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy.接受腹膜切除术和热灌注腹腔化疗治疗的腹膜恶性肿瘤患者的回顾。
ANZ J Surg. 2006 Mar;76(3):156-61. doi: 10.1111/j.1445-2197.2006.03579.x.
9
Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).腹膜假黏液瘤:接受细胞减灭术和腹腔内热灌注化疗(HIPEC)治疗患者的临床病理及生物学预后因素
Ann Surg Oncol. 2008 Feb;15(2):526-34. doi: 10.1245/s10434-007-9691-2. Epub 2007 Nov 28.
10
Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.细胞减灭术联合腹腔热灌注化疗(HIPEC)治疗腹膜假黏液瘤:十二年经验的结果分析
In Vivo. 2009 Jul-Aug;23(4):639-44.

引用本文的文献

1
A Clinical Pharmacological Perspective on Intraperitoneal Chemotherapy.腹腔内化疗的临床药理学视角
Drugs. 2025 May 24. doi: 10.1007/s40265-025-02195-9.
2
Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer.局部化疗方法与先进药物递送策略:卵巢癌腹膜癌治疗的新进展。
Front Oncol. 2023 May 23;13:1125868. doi: 10.3389/fonc.2023.1125868. eCollection 2023.
3
Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives.
腹膜转移的腹腔内化疗:技术创新、临床前和临床进展以及未来展望。
Biology (Basel). 2021 Mar 15;10(3):225. doi: 10.3390/biology10030225.
4
Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer.用于上皮性卵巢癌热灌注化疗(HIPEC)的卡铂的药代动力学及毒性
Pleura Peritoneum. 2020 Sep 7;5(4):20200137. doi: 10.1515/pp-2020-0137. eCollection 2020 Nov.
5
The PEritoneal SUrface CAlculator (PESUCA): A new tool to quantify the resected peritoneal surface area after cytoreductive surgery.腹膜表面积计算器(PESUCA):一种用于量化细胞减灭术后切除腹膜表面积的新工具。
Pleura Peritoneum. 2020 Feb 26;5(1):20190031. doi: 10.1515/pp-2019-0031. eCollection 2020 Mar 1.
6
Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review.基于白蛋白的癌症治疗药物用于腹腔内药物递送:综述。
Drug Deliv. 2020 Dec;27(1):40-53. doi: 10.1080/10717544.2019.1704945.
7
Modelling drug transport during intraperitoneal chemotherapy.腹腔内化疗期间药物转运的建模
Pleura Peritoneum. 2017 Jun 1;2(2):73-83. doi: 10.1515/pp-2017-0004. Epub 2017 Apr 14.
8
Pharmacological principles of intraperitoneal and bidirectional chemotherapy.腹腔内及双向化疗的药理学原理
Pleura Peritoneum. 2017 Jun 1;2(2):47-62. doi: 10.1515/pp-2017-0010. Epub 2017 Apr 29.
9
Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure.腹腔内热灌注化疗联合奥沙利铂治疗腹膜转移癌:手术治疗的临床药理学视角。
Br J Clin Pharmacol. 2019 Jan;85(1):47-58. doi: 10.1111/bcp.13773. Epub 2018 Oct 25.
10
Potentiation of chemotherapeutics by bromelain and N-acetylcysteine: sequential and combination therapy of gastrointestinal cancer cells.菠萝蛋白酶和N-乙酰半胱氨酸对化疗药物的增效作用:胃肠道癌细胞的序贯和联合治疗
Am J Cancer Res. 2016 Jan 15;6(2):350-69. eCollection 2016.